LGNDLigand Pharmaceuticals, Inc. - Ordinary Shares - Class B

In recent trading, shares of Ligand Pharmaceuticals Inc (Symbol: LGND) have crossed above the average analyst 12-month target price of $271.00, changing hands for $274.88/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: down...

Key PointsKozarich sold 2,501 common shares...

Key Points5,000 shares were sold for a total transaction value of ~$1.14 million on June 1, 2026, at a weighted average price around $227.06 per share...

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) insider Andrew Reardon sold 5,000 shares of the business's stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $231.31, for a total transaction of $1,156,550.00. Following the completion of the...

Kornitzer Capital Management Inc. KS lessened its stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 33.8% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 60,342 shares of the biotechnology compan...

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) - Stock analysts at HC Wainwright lifted their Q3 2026 earnings per share estimates for Ligand Pharmaceuticals in a research note...

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) has earned an average rating of "Moderate Buy" from the eight brokerages that are currently covering the company, Marketbeat...

HC Wainwright boosted their target price on Ligand Pharmaceuticals from $243.00 to $289.00 and gave the company a "buy" rating in a research report on Thursday...

Ligand Pharmaceuticals (NASDAQ:LGND) Shares Gap Down - What's Next...